232 related articles for article (PubMed ID: 32782585)
1. xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma.
Sugiyama A; Ohta T; Obata M; Takahashi K; Seino M; Nagase S
Oncol Lett; 2020 Sep; 20(3):2689-2700. PubMed ID: 32782585
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of Cell Death by Combined Treatment with an xCT Inhibitor and Paclitaxel: An Alternative Therapeutic Strategy for Patients with Ovarian Clear Cell Carcinoma.
Idei U; Ohta T; Yamatani H; Seino M; Nagase S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511540
[TBL] [Abstract][Full Text] [Related]
3. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer.
Kim EH; Shin D; Lee J; Jung AR; Roh JL
Cancer Lett; 2018 Sep; 432():180-190. PubMed ID: 29928961
[TBL] [Abstract][Full Text] [Related]
4. Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells.
Okazaki S; Shintani S; Hirata Y; Suina K; Semba T; Yamasaki J; Umene K; Ishikawa M; Saya H; Nagano O
Oncotarget; 2018 Sep; 9(73):33832-33843. PubMed ID: 30333913
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Sehm T; Rauh M; Wiendieck K; Buchfelder M; Eyüpoglu IY; Savaskan NE
Oncotarget; 2016 Nov; 7(46):74630-74647. PubMed ID: 27612422
[TBL] [Abstract][Full Text] [Related]
6. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
[TBL] [Abstract][Full Text] [Related]
7. Sulfasalazine‑induced ferroptosis in breast cancer cells is reduced by the inhibitory effect of estrogen receptor on the transferrin receptor.
Yu H; Yang C; Jian L; Guo S; Chen R; Li K; Qu F; Tao K; Fu Y; Luo F; Liu S
Oncol Rep; 2019 Aug; 42(2):826-838. PubMed ID: 31173262
[TBL] [Abstract][Full Text] [Related]
8. Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer.
Sendo K; Seino M; Ohta T; Nagase S
Oncotarget; 2022; 13():224-236. PubMed ID: 35106124
[TBL] [Abstract][Full Text] [Related]
9. Sulfasalazine impacts on ferroptotic cell death and alleviates the tumor microenvironment and glioma-induced brain edema.
Sehm T; Fan Z; Ghoochani A; Rauh M; Engelhorn T; Minakaki G; Dörfler A; Klucken J; Buchfelder M; Eyüpoglu IY; Savaskan N
Oncotarget; 2016 Jun; 7(24):36021-36033. PubMed ID: 27074570
[TBL] [Abstract][Full Text] [Related]
10. xCT Inhibition Increases Sensitivity to Vorinostat in a ROS-Dependent Manner.
Miyamoto K; Watanabe M; Boku S; Sukeno M; Morita M; Kondo H; Sakaguchi K; Taguchi T; Sakai T
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235498
[TBL] [Abstract][Full Text] [Related]
11. PGRMC1-dependent lipophagy promotes ferroptosis in paclitaxel-tolerant persister cancer cells.
You JH; Lee J; Roh JL
J Exp Clin Cancer Res; 2021 Nov; 40(1):350. PubMed ID: 34749765
[TBL] [Abstract][Full Text] [Related]
12. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
13. The Styryl Benzoic Acid Derivative DC10 Potentiates Radiotherapy by Targeting the xCT-Glutathione Axis.
Sarowar S; Cirillo D; Játiva P; Nilsen MH; Otragane SA; Heggdal J; Selheim F; Ceña V; Bjørsvik HR; Enger PØ
Front Oncol; 2022; 12():786739. PubMed ID: 35198439
[TBL] [Abstract][Full Text] [Related]
14. Polyphyllin Ⅲ-Induced Ferroptosis in MDA-MB-231 Triple-Negative Breast Cancer Cells can Be Protected Against by KLF4-Mediated Upregulation of xCT.
Zhou Y; Yang J; Chen C; Li Z; Chen Y; Zhang X; Wang L; Zhou J
Front Pharmacol; 2021; 12():670224. PubMed ID: 34040532
[TBL] [Abstract][Full Text] [Related]
15. Sulfasalazine inhibits esophageal cancer cell proliferation by mediating ferroptosis.
Yin LB; Li ZW; Wang JL; Wang L; Hou L; Hu SY; Chen H; Luo P; Cui XB; Zhu JL
Chem Biol Drug Des; 2023 Oct; 102(4):730-737. PubMed ID: 37291716
[TBL] [Abstract][Full Text] [Related]
16. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
[TBL] [Abstract][Full Text] [Related]
17. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
Roh JL; Kim EH; Jang H; Shin D
Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
[TBL] [Abstract][Full Text] [Related]
18. Edaravone, a free radical scavenger, protects against ferroptotic cell death in vitro.
Homma T; Kobayashi S; Sato H; Fujii J
Exp Cell Res; 2019 Nov; 384(1):111592. PubMed ID: 31479686
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway.
Wang SF; Chen MS; Chou YC; Ueng YF; Yin PH; Yeh TS; Lee HC
Oncotarget; 2016 Nov; 7(45):74132-74151. PubMed ID: 27708226
[TBL] [Abstract][Full Text] [Related]
20. Genetic Ablation of the Cystine Transporter xCT in PDAC Cells Inhibits mTORC1, Growth, Survival, and Tumor Formation via Nutrient and Oxidative Stresses.
Daher B; Parks SK; Durivault J; Cormerais Y; Baidarjad H; Tambutte E; Pouysségur J; Vučetić M
Cancer Res; 2019 Aug; 79(15):3877-3890. PubMed ID: 31175120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
